Cardiol Therapeutics Inc.

TSX:CRDL.TO

Drug Manufacturers - Specialty & Generic

Healthcare
$1.36 +0.67%

+$0.00 today

Market cap
$164.10M
Beta
0.48
P/E (TTM)
-4.5
EPS (TTM)
-$0.33
52W Low $1.23High $2.33

Volume 0.08M

Average 0.12M

Returns on capital

Cardiol Therapeutics Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-189.2%

avg -96.9%

ROIC

-190.6%

avg -96.7%

ROA

-143.2%

avg -79.7%

Analysis

ROA is currently the strongest return metric at -143.2% versus its period average of -79.7%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Andrew Warwick Hamer

Chief Medical Officer and Head of Research & DevelopmentCAD 801.66K64——

David G. Elsley

President, Chief Executive Officer & DirectorCAD 774.4K———

Bernard Lim

Chief Operating OfficerCAD 531.3K———

Christopher J. Waddick

Chief Financial Officer, Corporate Secretary & DirectorCAD 303.6K———

John A. Geddes BSCPT

Vice President of Corporate Development————

Trevor Burns

Investor Relations————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

No open-market purchases or sales in the last 12 months.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/AN/A
N/A3 analysts
Net IncomeN/AN/AN/A
N/A3 analysts
EBITN/AN/AN/A
N/A3 analysts

Analysis

Analysis will appear once historical growth or forward estimates are available for this company.

Competitors

Who does Cardiol Therapeutics Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about CRDL.TO's management, answered from reported figures.

Who manages CRDL.TO?

Cardiol Therapeutics Inc. (CRDL.TO) lists 6 active executives. The top listed executive is Andrew Warwick Hamer, Chief Medical Officer and Head of Research & Development.